Harness the healing power of the melanocortin system
We discover and develop novel therapeutics for the treatment of obesity (primary focus on rare neuroendocrine diseases), inflammatory, and autoimmune conditions.
By leveraging deep expertise in receptor pharmacology and peptide/small-molecule design, we are developing highly selective melanocortin agonists engineered to modulate specific receptor subtypes (including MC1R and MC4R) while minimizing off-target effects.
This precision approach enables us to target complex, multifactorial diseases with novel mechanisms of action, supporting the development of therapies that can address significant unmet medical needs across obesity, inflammatory, and autoimmune indications.
Our Science
We are advancing a differentiated therapeutic platform centered on the melanocortin receptor (MCR) system, a biologically validated pathway with broad regulatory control over appetite, energy homeostasis, inflammation, and immune response.
Our Pipeline
Our lead development efforts are focused on MC4R agonists for the treatment of obesity, with a primary emphasis on rare neuroendocrine disorders such as hypothalamic obesity (HO) and Prader-Willi syndrome (PWS).
Join Us
At Palatin, we drive our culture with science. Our employees have unparalleled expertise related to the melanocortin system allowing them to develop potent, selective treatments for patients with unmet medical needs.
NEWS
Our press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
RESOURCES
Take a look at the latest on Palatin across our media publications, posters, and presentations.